Global Hypertension in CKD Market
Global Hypertension in CKD Market had a valuation of US$ 191.8 million in 2020 and is anticipated to grow at a CAGR of 10.6% during the forecast period (2020-2027).
Expanding innovative work exercises by the central members is projected to drive the development of the global hypertension in CKD market over the estimated timeframe. On December 7, 2020, KBP Biosciences Holdings Limited reported positive outcomes from its Phase 2b clinical preliminary of its lead competitor, KBP-5074. KBP-5074 is a non-steroidal mineralocorticoid receptor adversary (MRA) that is being created to treat patients experiencing ongoing kidney sickness and uncontrolled hypertension.
Free Sample Copy of Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/4431
Effect of the Coronavirus (COVID-19) Pandemic
Over the forecast timeframe, the COVID-19 pandemic is expected to limit global hypertension in the CKD market. As indicated by the National Center for Biotechnology Information (NCBI) on September 29, 2020, the therapy for persistent kidney sickness may be postponed as a result of the pandemic. In addition, during the COVID-19 pandemic, the treatment of kidney issue patients is delayed or even dropped due to the inaccessibility of sporadic inventory and transportation of medications.
Furthermore, as reported by the United States Food and Drug Administration (FDA) on September 18, 2020, the COVID-19 pandemic has disrupted the global medication supply as a result of government-ordered or suggested temporary closures, security drives to ensure representative wellbeing and prosperity, an insufficient workforce, and restrictions on import and commodity exercises and travel.
The increasing predominance of persistent kidney illness (CKD) and diabetic kidney infection (DKD) among the age groups is projected to drive the global hypertension in CKD market development over the conjectured timeframe. As per the Centers for Disease Control and Prevention (CDC), March 4, 2021, in the U.S., around 15% of the U.S. grown-ups, or 37 million individuals, are as of now experiencing ongoing kidney infection.
Get Quick Access To PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/4431
Furthermore, according to the National Institute of Diabetes and Digestive and Kidney Diseases in 2020, high blood glucose levels can harm the veins in the kidneys, as many diabetics also have hypertension. This is called diabetic kidney illness (DKD) in type 2 diabetes. According to the National Center for Biotechnology Information (NCBI): 2017, the prevalence of DKD in most types 2 diabetics at any time is roughly 30%–half of all diabetic adults in the United States. This pervasiveness was going from 25% in patients more youthful than 65 years of age to almost half in those older than 65 years. Consequently, patients experiencing DKD have a higher possibility of experiencing hypertension.
Key Takeaways
The global hypertension in CKD market is projected to grow at a CAGR of 10.6% over the estimate period (2020–2027), attributable to the rising pervasiveness of CKD.
North America represented a significant portion of the overall industry as a result of the increasing commonness of hypertension in end-stage kidney illness, which is anticipated to drive the global hypertension in CKD market development over the conjectured timeframe. As indicated by the Centers for Disease Control and Prevention (CDC) assessments in 2019, hypertension was seen in patients aged 65 or above and experiencing constant kidney infection, and as per a similar source, roughly 125,000 individuals in the U.S. began treatment for end-stage kidney infection (ESKD) and nearly 726,000 (2 in every 1,000 individuals) in 2018 were on dialysis or had gone through kidney relocation.
Key companies contributing to the global hypertension in CKD market include, C.H. Boehringer Sohn AG & Ko. KG, AstraZeneca Plc, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Sanofi S.A, KBP Biosciences Holdings Limited, Ardelyx, Reata Pharmaceuticals, Inc., Novartis International AG, and Kissei Pharmaceutical Co., Ltd.
To Purchase Report, Click Here – https://www.coherentmarketinsights.com/insight/buy-now/4431
Table of Contents
- Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- Market Overview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Class
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Epidemiology
- Key Developments
- Pipeline analysis
- Regulatory Scenario
- Reimbursement Scenario
- PEST Analysis
- Treatment Approaches
- Mergers and Acquisitions Scenario
- Market Dynamics
- Global Hypertension in CKD Market – Impact of Coronavirus (Covid-19) Pandemic
- During COVID-19 Market Situation
- Supply Side and Demand Side Analysis
- Government Initiatives for Management of Hypertension in Chronic Kidney Disease (CKD)
- Global Hypertension in CKD Market, By Drug Class, 2016-2027 (US$ Million)
- Introduction
- Market Share Analysis, 2020 and 2027 (%)
- Y-o-Y Growth Analysis, 2017 – 2027
- Segment Trends
- Diuretics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- RAS Blockade
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- β – Blockers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Calcium Channel Blockers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Introduction
- Global Hypertension in CKD Market, By Distribution Channel, 2016 – 2027 (US$ Million)
- Introduction
- Market Share Analysis, 2020 and 2027 (%)
- Y-o-Y Growth Analysis, 2017 – 2027
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Introduction
View Press Release: https://www.coherentmarketinsights.com/press-release/hypertension-in-ckd-market-3694
About US:
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837